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Abstract
Introduction: Population-wide HIV testing services (HTS) must be delivered in order to achieve universal antiretroviral
treatment (ART) coverage. To accurately deliver HTS at such scale, non-facility-based HIV point-of-care testing (HIV-POCT) is
necessary but requires rigorous quality assurance (QA). This study assessed the performance of community-wide HTS in
Zambia and South Africa (SA) as part of the HPTN 071 (PopART) study and explores the impact of quality improvement
interventions on HTS performance.
Methods: Between 2014 and 2016, HIV-POCT was undertaken within households both as part of the randomly selected HPTN
071 research cohort (Population Cohort [PC]) and as part of the intervention provided by community HIV-care providers. HIV-
POCT followed national algorithms in both countries. Consenting PC participants provided a venous blood sample in addition to
being offered HIV-POCT. We compared results obtained in the PC using a laboratory-based gold standard (GS) testing algorithm
and HIV-POCT. Comprehensive QA mechanisms were put in place to support the community-wide testing. Participants who
were identified as having a false negative or false positive HIV rapid test were revisited and offered retesting.
Results: We initially observed poor sensitivity (45–54%, 95% confidence interval [CI] 31–69) of HIV-POCT in the PC in SA
compared to sensitivity in Zambia for the same time period of 95.8% (95% CI 93–98). In both countries, specificity of HIV-
POCT was >98%. With enhanced QA interventions and adoption of the same HIV-POCT algorithm, sensitivity in SA improved
to a similar level as in Zambia.
Conclusions: This is one of the first reports of HIV-POCT performance during wide-scale delivery of HTS compared to a GS
laboratory algorithm. HIV-POCT in a real-world setting had a lower sensitivity than anticipated. Appropriate choice of HIV-
POCT algorithms, intensive training and supervision, and robust QA mechanisms are necessary to optimize HIV-POCT test
performance when testing is delivered at a community level. HIV-POCT in clients who did not disclose that they were on ART
may have contributed to false negative HIV-POCT results and should be the topic of future research.
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Introduction
Globally, 37 million people are estimated to be living with
HIV [1]. In 2014, UNAIDS announced a global target of 90%
of HIV-positive individuals knowing their HIV status in order
to deliver universal access to antiretroviral treatment (ART)
for all people living with HIV (PLWH) [2]. However, there
remains a considerable HIV testing gap, with only 54% of
PLWH aware of their HIV status in 2014 [3]. Reaching the
UNAIDS 90-90-90 targets will require a massive scale-up of
HIV testing and will necessitate innovative strategies to
achieve this goal.
Whilst HIV testing services (HTS) are usually provided at
healthcare facilities, multiple barriers prevent wide-scale
access and acceptance of testing through this approach
[4]. To improve knowledge of HIV status, non-facility-
based HIV testing approaches have been explored [5,6]
and many are now integrated into community testing pro-
grammes [5,7–9]. Previous studies have shown high levels
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of competency in HIV testing amongst counsellors in house-
hold settings [10,11], and high levels of acceptance for
community-based HIV testing are reported [5]. However,
the quality assurance (QA) of this mode of HIV testing
may be more challenging. The sensitivity and specificity of
HIV point-of care testing (HIV-POCT) may be affected by
user training and competency, testing environments, the
algorithm used, test kit handling and storage as well as
test kit performance [12–14]. Sensitivity and specificity of
commonly used HIV-POCT in laboratory conditions are high
(consistently 97–99%) [5,15,16]. However, there are limited
and varied data on the performance of HIV-POCT in field
settings, and comparison to a laboratory-based gold stan-
dard (GS) is uncommon [15,16]. The World Health
Organization (WHO) pre-qualifies certain HIV testing strate-
gies [7], but countries may utilize algorithms based on price
and availability of test kits.
HIV-POCT QA guidelines vary across settings. The WHO
emphasizes the importance of QA supported by well-struc-
tured quality management services and has recently
updated its guidance for establishing HIV testing QA. The
WHO recommends using a combination of quality control
(QC) of HIV test kits and monitoring of proficiency of the
staff conducting tests using both internally and externally
generated plasma panels [7]. Effective implementation of
these guidelines is resource-intensive and requires basic
equipment and laboratory infrastructure that may be diffi-
cult to access in many high-burden settings [7].
HPTN 071 (PopART) is a community-randomized trial
investigating the impact of a combination HIV prevention
package on HIV incidence. The design of the study has
been reported previously [17]. A key component of the
combination prevention package is community-wide HIV
testing offered by a novel cadre of community HIV-care
providers (CHiPs) within the households of consenting
individuals using HIV-POCT. CHiPs workers are “lay coun-
sellors” who have a minimum of grade 11 or 12 high
school education prior to employment and received
basic accredited HIV counselling and testing training
prior to conducting HIV-POCT in the field. In parallel
with the CHiPs HIV testing, a randomly selected research
Population Cohort (PC) of participants consented to pro-
vide an annual blood sample to determine HIV status in
study laboratories for the study’s primary endpoint; many
of these individuals also accept optional HIV-POCT deliv-
ered by research nurses in their households. This cohort
provides an opportunity to assess performance of com-
munity-wide HIV-POCT compared to a laboratory-based
GS. This manuscript describes the performance of com-
munity-wide HIV-POCT in Zambia and South Africa (SA) as
part of the HPTN 071 (PopART) study.
Methods
Within each of the 21 communities in Zambia and SA
included in the HPTN 071 (PopART) study, a random sample
of approximately 2000 participants aged between 18 and
44 years were selected to join the PC. Consenting partici-
pants were visited in their households and asked to provide
a venous sample of blood for laboratory-based HIV testing
(blinded for study arm) to inform the study primary end-
point (HIV incidence). Results of this laboratory HIV testing
were not routinely returned to study participants. All parti-
cipants were encouraged to undergo HIV-POCT using the
current nationally approved test algorithm. The results of
this testing were given directly to the participant. Not all PC
participants chose to have a HIV-POCT; some may already
have been tested by the CHiPs or have previously known
their status. For this paper, data from the baseline survey of
the PC (PC0) and the 12-month follow-up survey (PC12)
were analysed.
HIV-POCT testing algorithms
In both Zambia and SA, HIV-POCT was undertaken by both
trained CHiPs (lay counsellors) for the community combina-
tion prevention intervention and research nurses for the
PC. In both cases, two HIV-POCT tests performed in series
were used, in line with national and local guidelines. In
Zambia, the Alere Determine™ HIV-1/2 test (Alere inc.,
CA, USA) was used for screening and the Uni-Gold HIV
test (Trinity Biotech, Bray, Co.Wicklow, Ireland) was used
for confirmation throughout the study period.
In SA testing followed the national algorithm which var-
ied during the study period. From January to June 2014, the
First Response™ HIV 1-2-0 Card Test (Real Relief India
Private Limited, Tamil Nadu, India) was used for screening
and the Alere Determine™ HIV-1/2 for confirmation; from
July to December 2014, SD Bioline HIV-1/2 3.0 (Alere, CA,
USA) for screening and Alere Determine™ HIV-1/2 test was
used for confirmation; from January to June 2015, the
ADVANCED QUALITY™ Rapid Anti-HIV (1&2) Test (InTec
Products Inc., Haicang, Xiamen, China) was used for screen-
ing and the Abon HIV 1/2/O Tri-line test (Alere Inc., CA,
USA) was used for confirmation. These changes in tests kits
matched those of the SA Department of Health (SADOH)
which provided the study with test kits during that period.
Following the analysis of the performance of these HIV-
POCT algorithms, the study team chose to provide kits for
SA HIV-POCT from July 2015 onwards such that Alere
Determine™ HIV-1/2 test was used for screening and the
Uni-Gold™ Recombigen® HIV-1/2 test was used for confir-
mation, to be consistent with the algorithm used in Zambia.
HIV-POCT quality management
A system of quality management for the HIV-POCT was
developed which included both QC for the test kits and
QA of the testing procedure (QA/QC). This system used
nationally available guidelines, but was expanded by the
study team to include internal quality control (IQC) panel
testing of test kits, temperature monitoring of test kits and
proficiency testing of all staff conducting HIV testing. In
Zambia, additional procedures were established earlier
than in SA, as initially the SA test kits were provided by
the DOH and QC systems used by DOH were assumed to be
adequate. The timing of the implementation of additional
procedures by the study team is shown in Table 1. Details
of the additional procedures are as follow:
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Table 1. Performance, test kits used and quality measures in Zambia (Z) and South Africa (SA)
Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016
Zambia
N (total test) 1317 2038 2346 2318 2103 0a 822 2002 2194 1140
Correctly identified HIV-
positive (HIV-POCT+/GS +)
229/238 231/248 197/221 213/235 146/157 48/51 125/130 124/130 70/74
Correctly identified HIV-
negative (HIV-POCT−/GS−)
1077/1079 1788/1790 2121/2125 2081/2083 1944/1946 767/771 1871/1872 2063/2064 1065/1066
Sensitivity % (95% CI) 96.2 (93–98) 93.1 (89–96) 89.1 (84–93) 90.6 (86–94) 93.0 (88–96) 94.1 (84–99) 89.9 (84–94) 95.4 (90–98) 94.6 (87–98)
Specificity % (95% CI) 99.8 (99.3–100) 99.9 (99.6–100) 99.8 (99.5–100) 99.9 (99.7–100) 99.9 (99.6–100) 99.5 (98.6–100) 99.9 (99.6–100) 100 (99.7–100) 99.9 (99.5–100)
Zambia first-line POCT Determine Determine Determine Determine Determine Determine Determine Determine Determine
Zambia second-line POCT Uni-Gold Uni-Gold Uni-Gold Uni-Gold Uni-Gold Uni-Gold Uni-Gold Uni-Gold Uni-Gold
IQC test strips/devices
(pass/tested)
67/67 95/95 615/615 752/752 423/423 1164/1164 2840/2840 2874/2874 3543/3543 2528/2528
Panel proficiency testing
(pass/total)
96/99 79/82 143/151 98/100l 108/110 141/144 120/124 55/55 102/106
South Africa
N (total test) 429 672 395 90 453 0a 1029 911 973 436
Correctly identified HIV-
positive (HIV-POCT +/GS +)
13/24 21/43 9/20 3/3 16/23 38/52 33/42 16/21 13/13
Correctly identified HIV-
negative (HIV-POCT−/GS−)
405/405 629/629 375/375 87/87 430/430 977/977 868/869 952/952 423/423
Sensitivity % (95% CI) 54.2 (33–74) 48.8 (33–65) 45.0 (23–68) b 69.6 (47–87) 73.1 (59–84) 78.6 (63–90) 76.2 (53–92) 100 (75–100)
Specificity % (95%CI) 100 (99–100) 100 (99–100) 100 (99–100) 100 (96–100) 100 (99–100) 100 (99.6, 100) 99.9 (99–100) 100 (99.6, 100) 100 (99–100)
SA first-line POCT First response First response SD Bioline SD Bioline Advance quality Advance quality Determine Determine Determine
SA second-line POCT Determine Determine Determine Determine Abon Abon Uni-Gold Uni-Gold Uni-Gold
IQC test strips/devices
(pass/tested)
1482/1482 556/556 718/718 2297/2297 2131/2131 3090/3090
Panel proficiency testing
(pass/total)
4/4 119/122 129/130 43/43 32/34 0
HIV-POCT+: final result of HIV-POCT algorithm is positive; HIV-POCT−: final result of HIV-POCT algorithm is negative; GS+: final result of laboratory algorithm is positive; GS−: final result of
laboratory algorithm is negative.
HIV-POCT: HIV point-of-care testing; IQC: internal quality control; GS: gold standard; QA: quality assurance; PC: Population Cohort.
aNo PC activity this quarter but QA continued.
bSensitivity not calculated due to small number of positive results.
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IQC panel testing of test kits was performed (i) when new
tests kits were delivered to study head office, (ii) after
transport of test kits to site offices within the communities
and (iii) monthly for test kits that had been stored at site
offices and transported in the field. Due to the large num-
ber of test kits used, panels used for IQC testing were
generated by each in-country study laboratory. In Zambia,
IQC activities described in this paper were initiated at the
beginning of the study whilst in SA QC of test kits was
conducted by the SADOH initially but was undertaken by
the study team from Q1 2015 onwards.
Temperature monitoring during test kit storage was con-
ducted in each country at the in-country study head office, at
field offices and in cooler boxes thatwere used to transport HIV-
POCT kits in the field. In instances where out-of-range tempera-
tureswere reported (>27°C for three consecutive days), IQCwas
performed for the affected test kits as described above.
User proficiency to perform the HIV-POCT kit procedures
according to the manufacturers’ specifications was assessed
among all PC research staff and among CHiPs. In both
countries, PC research nurses and CHiPs completed regular
internal and external proficiency testing (EQA).
A checklist was developed to be used for observation of
all staff performing HIV-POCT. This checklist covered all
aspects of home-based testing, including: preparing the
testing environment, obtaining a finger stick sample, carry-
ing out testing and interpreting results (see Appendix). In
addition, in both countries, internal proficiency panel test-
ing was done with blinded plasma panels of HIV-positive
and HIV-negative samples at least once per year for all
testers. EQA with samples provided by the National
Health Laboratory Service (NHLS) in SA and the National
Virology Reference Laboratory (NVRL) in Zambia was also
conducted on an annual basis from 2015 when these panels
were made available.
If an individual staff member failed internal- or external
proficiency testing, the individual underwent re-training
and repeat proficiency testing before being allowed to
resume HIV testing.
Laboratory-based HIV testing
In this large clinical trial, special algorithms were developed
for laboratory-based HIV testing in the PC. In addition to
HIV-POCT described above which was part of the study
intervention, venous blood was collected from each PC
study participant for laboratory-based testing to provide
data for the primary study endpoint of HIV incidence. This
testing was done in two stages. In the first step, a single HIV
screening assay (Abbott Architect Combo) was performed
in-country. The results of that test dictated the algorithm
that was used at the HPTN Laboratory Center (HPTN-LC,
Johns Hopkins Univ. School of Medicine, Baltimore, MD,
USA) for QA and HIV confirmation. For 10% of the samples
where the in-country test was non-reactive, testing was
repeated at the HPTN-LC with the same 4th generation
test (the Abbott Architect Combo). If the results of the
two tests were discrepant, samples were tested with the
4th generation Bio-Rad HIV 1/2 Combo (Bio-Rad Combo
test) and the Bio-Rad Geenius discriminatory assay. For all
samples that had a reactive in-country test, testing was
performed at the HPTN-LC with a different 4th generation
test (the Bio-Rad 4th generation assay). If the in-country
and HPTN-LC test results were discrepant, samples were
tested at the HPTN-LC with Abbott Architect assay, the Bio-
Rad Geenius discriminatory assay and HIV viral load testing.
The final HIV status determined at the HPTN-LC is defined
in this paper as the GS. Results of HIV tests performed in
the in-country laboratories and at the HPTN-LC were not
reported to study participants, unless discrepancies were
identified between HIV-POCT among those who accepted
the testing and final laboratory test results.
Management of discrepant results between laboratory
test and HIV-POCT
In both countries, PC participants who had discrepant
results for the laboratory-based test and HIV-POCT were
revisited by the research staff and offered the opportunity
for repeat HIV testing using HIV-POCT; this was followed by
collection of an additional venous blood sample in cases
where the HIV-POCT was still discrepant with the laboratory
result. Information was also collected regarding prior
knowledge of HIV status, engagement in care if aware of
HIV-positive status and ART at the time of initial HIV-POCT.
Data management and statistical analysis
Data for all PC participants were collected electronically
using a specially designed database. All participants were
identified by a unique barcode. HIV-POCT results were
recorded first on a barcoded paper-based results form by
the nurse, and this information was entered into the elec-
tronic data capture device at the end of each day by the
research assistant. All blood samples were labelled using
the participant barcode and sent to laboratories for proces-
sing within 6 h of blood draw. Aliquots of plasma were
stored at −80°C until laboratory testing. All laboratory data
were entered into a laboratory data management system.
In the case of discrepant results between laboratory test
and HIV-POCT, data entry errors were excluded by retrieval
of the source document HIV-POCT form and comparison
and correction on the electronic data base.
This analysis of performance of HIV-POCT compared to a
laboratory reference standard was limited to those PC
participants with both an HIV-POCT result and a laboratory
HIV test result corresponding to PC visits taking place
between January 2014 and June 2016. Estimates of sensi-
tivity and specificity of HIV-POCT over time, with exact
binomial 95% confidence intervals (95% CI), were calculated
in order to assess the possible effects of test kit choice and
improvement in quality management.
Ethical approval
Ethical approval for the HPTN 071 study was obtained from the
University of Zambia research ethics committee, Stellenbosch
University health research ethics committee and the London
School of Hygiene and Tropical Medicine ethics committee.
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Results
Study population
Data analysed in this paper include 21,668 paired HIV-POCT
and laboratory GS results obtained from 17,680 PC partici-
pants at the PC enrolment and/or 12-month follow-up
surveys (16,280, 75.1% Zambia, 5388, 24.9% SA).
HIV-POCT performance
Using data from PC participants who had both HIV-POCT
and laboratory results available, we examined HIV-POCT
performance over time by quarter. Figure 1 summarizes
HIV-POCT sensitivity for each country. Table 1 shows sensi-
tivity and specificity by country over time alongside the test
kit algorithms and other quality management activities.
Data from Zambia for the entire period showed a
sensitivity of 89–96%, with the lower limit of the 95%
CI remaining above 84% throughout. However, the sensi-
tivity of HIV-POCT in SA was very different, with
observed sensitivity as low as 45%.
In SA the test kit algorithm changed first in Q3 2014 in line
with SA national guideline change and again in Q1 2015.
Neither of these changes in HIV-POCT algorithm appeared to
significantly change the performance of the testing process.
As a consequence of continuing poor performance in SA,
HIV-POCT algorithm was changed in Q4 2015 to be consis-
tent with that used in Zambia (Alere Determine™ HIV-1/2
followed by Uni-Gold™ Recombigen® HIV-1/2). Additional
quality management procedures were also employed to
monitor HIV-POCT performance, similar to what was being
implemented in Zambia. These included re-training of all
staff and more frequent staff supervision. Proficiency testing
using approved plasma panels was introduced.
Quality assurance
IQC testing was performed on a total of 25,175 test strips/
devices overall at central storage and field sites, as well as
when temperature monitoring showed deviations from the
recommended storage temperatures in storage sites or
field cooler boxes. On all occasions, the test strips/devices
tested, passed (IQC) (Table 1).
Internal proficiency panel testing was conducted annually
so that during this period individual testers may have been
tested more than once. A total of 971 proficiency panels
were used (934 for CHiPs and 37 for PC nurses) in Zambia
with an overall pass rate of 96% (Table 1). External profi-
ciency panel testing was conducted once during the period
of this report and 419/444 testers (94%) passed (20 PC
nurses were tested with 100% pass rate). In SA, internal
proficiency panel testing started later and a total of 333
proficiency panels being used (271 for CHiPs and 62 for PC
nurses) with an overall pass rate of 98%. All individuals
failing proficiency panel testing were re-trained and had
to pass a further proficiency panel test before being
allowed to resume testing. External panel proficiency test-
ing was conducted in the six HPTN 071 intervention sites
with one panel per site being tested rather than individual
testers. All six sites were tested on four occasions with one
site failing on one occasion. This site received additional re-
training.
Observation of all steps in the HIV-POCT process using
the supervision checklist started in 2015, and observations
using this revealed that most errors were made in the
finger stick and correct use of the sample collection device
(capillary tube or pipette according to test used). Errors
were also made in the timing and amount of chase buffer
added.
Figure 1. Sensitivity of HIV-POCT in Zambia and South Africa by quarter. HIV-POCT: HIV point-of-care testing.
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Follow-up of individuals with discrepant HIV-POCT and
laboratory tests
Overall, 199 participants had 200 discrepant HIV results
(participants were seen annually so it was possible for
them to receive discrepant results in both years). Figure 2
summarizes for each country the follow-up of participants
with test results that were discrepant between the HIV-
POCT and the laboratory GS. In Zambia 120 and in SA 80
participants were identified with discrepant results.
Multiple attempts to revisit all these participants were
made by the research teams in both countries, according
to a standardized algorithm, during which these partici-
pants were offered a repeat HIV-POCT and laboratory
test. There were some differences in the procedures for
conducting re-test visits between Zambia and SA.
In SA, re-test visits have been attempted for all 80 parti-
cipants with confirmed discrepant results. PC staff were
unable to locate 10 participants, and a further 10 declined
a re-test visit, for the remaining 60 participants, 59
appeared to have initial false negative results (HIV-POCT-
negative but GS-positive) and 1 an initial false positive
result (HIV-POCT-positive but GS-negative). Of the 59 indi-
viduals with false negative results, 37 (63%) were found to
already know their HIV-positive status and 26 (44%) were
confirmed to be on ART at the time of the false negative
POCT. Re-testing was not performed on known HIV-posi-
tives; however, they were given adherence counselling and
advised to attend the clinic. For the remaining 22 indivi-
duals, HIV-POCT was repeated using the algorithm of Alere
Determine™ HIV-1/2 and Uni-Gold™ Recombigen® HIV-1/2.
Three of these participants again tested HIV-negative on
HIV-POCT. Of these, two did not consent to further blood
draw for plasma HIV testing and one tested HIV-negative on
further in-country laboratory testing. Investigation of this
participant was terminated after the participant was lost to
follow-up due to relocation out of the study area. Including
individuals known to be HIV–positive, a total of 56/59 (95%)
were confirmed to have been prior false negative HIV-POCT
results. One participant had a false positive HIV rapid test;
this participant was re-visited and on re-testing with HIV-
POCT tested HIV-negative.
In Zambia, the picture was different. Of the 120 partici-
pants with discrepant results, 29 terminated participation
at a subsequent PC visit (moved out, not found or refused
further participation). Due to delays in laboratory results
and receipt of source data from remote sites, the follow-up
results of a further 38 participants could not be included.
Of the remaining 53 participants followed up, 7 participants
10 Not found 
0 not yet followed up  
10 refused further
testing  
70 followed up
80 discrepant results
(79 HIV-POCT-/GS+ and 
1 HIV-POCT+/GS-)
1  HIV-POCT+,GS- 
0 Inconclusive
HIV-POCT
59 HIV-POCT-,GS+ 
 1  tested HIV - on NHLS
laboratory testing
2 refused NHLS 
laboratory testing
 3 HIV-POCT- on 
retesting
19 HIV-POCT+ on 
retesting 
1  HIV-POCT- on
retesting 
 37 known HIV positive of whom 26
on ART
Figure 2a. Flow chart of follow up of participants with discrepant HIV results South Africa.
HIV-POCT: HIV point-of-care testing. HIV-POCT−: original HIV-POCT algorithm negative; HIV-POCT+: original HIV-POCT algorithm positive;
inconclusive HIV-POCT−: original HIV-POCT algorithm discordant; GS+: laboratory algorithm (gold standard) HIV positive; GS−: laboratory
algorithm negative; GS confirmed: after retesting the HIV-POCT agreed with the laboratory gold standard; HIV-POCT confirmed: after
retesting the results of the repeat HIV-POCT algorithm agreed with the original HIV-POCT algorithm.
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declined further testing, leaving 46 of whom 38 initially
appeared to have false negative HIV-POCT results (HIV-
POCT-negative but GS-positive), 7 false positive results
(HIV-POCT-positive but GS-negative) and 1 an inconclusive
HIV-POCT result (discordant results between the two rapid
tests used as the HIV-POCT algorithm, GS-positive). Of the
38 individuals with false negative results, 5 (13%) were
already known to be HIV-positive and taking ART. The
majority, 21 (55%), had repeat HIV-POCT results consistent
with the original negative HIV-POCT, demonstrating some
inherent differences between the laboratory and HIV-POCT
and some possible laboratory errors. For the remaining 12
(32%), repeat HIV-POCT confirmed the positive laboratory
result. For five out of seven apparent false positives, the
repeat HIV-POCT was negative, the other two participants
were confirmed to be HIV-positive, one participant con-
firmed that they were on ART and for the other repeat
HIV-POCT and laboratory testing confirmed a positive
result. Finally, the participant with an inconclusive HIV-
POCT stated they were on ART at the follow-up visit.
Discussion
Expanding high-quality community-based HIV-POCT is critical
if high burden communities are to achieve the UNAIDS 90-90-
90 targets. The HPTN 071 (PopART) study offered a unique
opportunity to assess the performance of HIV-POCT con-
ducted in the homes of over 17,000 participants in urban
and peri-urban high HIV-burden communities in Zambia and
SA. Through comparison of results from field (household) HIV-
POCT testing with laboratory-based testing on venous blood
samples, we noted that despite careful and repeated user
training and assessment and monitoring of cold chain storage
of HIV-POCT kits, the sensitivity of field HIV-POCT is less than
that reported for laboratory-based HIV testing [16].
The situation in the SA sites demonstrated a “perfect
storm” of poor choice of HIV-POCT algorithms, inadequate
QA and user error. It is impossible to identify which con-
tributed most to the poor performance. The requirement
for staff re-training to accommodate frequent changes in
the type of HIV-POCT kits procured by SADOH is likely to
have contributed to user error in this setting. Change in
HIV-POCT kits to consistent use of a well-established algo-
rithm in combination with strengthened training, supervi-
sion and quality management all played a part in improving
the performance.
One critical stage in the performance of HIV-POCT is
sample collection. This involves the use of different man-
ufacturer-provided sample collection tools some of which
are challenging for non-laboratory staff to use, for exam-
ple, the capillary tube device. Additionally, some manu-
facturers offer complete kits but also sell the components
individually which may result in HIV-POCT being con-
ducted without the correct sample collection device.
Panel proficiency testing does not test this step and
whilst the use of dried samples, as is currently recom-
mended by WHO for QA, allows for easier shipment of
QA materials, it requires different skills in rehydration
1 Inconclusive HIV-
POCT
1 Confirmed on ART
7 HIV-
POCT+GS-
5 confirmed
on ART
1 Confirmed
on ART
5 HIV-POCT- 
on retesting
38 Not yet 
followed up
53 Followed
up
1 GS+ on 
retesting
12 GS- on
retesting
21 HIV-POCT-
on retesting
12 HIV-
POCT+ on
retesting
8 No blood
collected
1 GS+ on
retesting
29 
Terminated
7 Refused
further
testing
38 HIV-POCT-
GS+
120 Discrepant results (100 
POCT-/GS+, 19 POCT+/GS- 
and 1 POCT 
inconclusive/GS+)
Figure 2b. Flow chart of follow up of participants with discrepant HIV results Zambia.
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and testing which do not reflect the real-life situation [7].
In the proficiency panel testing for this study with over
700 nurses and lay counsellors, the pass rate was consis-
tently high (>95%), but user errors were detected when
we implemented our increased supervision and use of a
checklist (Appendix) which ensures that testers are
assessed for proficiency in all stages of testing, including
sample collection as well as counselling.
IQC of test kits after exposure to out-of-range tempera-
tures in both countries did not reveal any functional
abnormalities, suggesting that in this study, this factor did
not contribute to the observed poor test kit performance.
The number of test kits tested during internal QA was very
large necessitating large quantities of positive and negative
controls to be produced at a significant cost.
The laboratory GS used in this study included combined
antigen–antibody 4th generation tests and viral load testing
and so 3rd generation HIV-POCT will never be able to per-
form as well. However, it is unlikely that even with the
anticipated differences in sensitivity between HIV-POCT
3rd generation antibody testing and laboratory testing, fail-
ure to identify acute infection was the primary driver of
decreased sensitivity. Accounting for missed acute infec-
tions, which can be assumed to account for only a small
proportion of the observed false negative HIV-POCT results,
the performance of community-wide HIV-POCT was still not
ideal. Laboratory testing, which was conducted during this
study, is extremely labour-intensive and time-consuming
and so it is not being recommended as an alternative to
HIV-POCT. There is, however, a need to balance the wide-
spread scale-up of HTS with quality of the results. Our
results from the re-visits to participants with discrepant
results in Zambia also show that laboratory testing may
also have errors, possibly due to sample mislabelling.
The finding of increased false negative results in those
individuals taking ART warrants further investigation. There
is a paucity of evidence for decreased sensitivity of POCT in
HIV-positive clients who are taking ART in the adult popula-
tion; however, there is emerging evidence of this in children
and adolescents [18,19]. HIV-POCT was not intended for
use among individuals on ART, and this was an unexpected
scenario in our study. In a “real-world” setting, this is a
potentially important finding which requires further
research and emphasizes the importance of appropriate
messaging when offering community-based HIV testing,
particularly with reference to limitation of HIV-POCT for
individuals on ART. Further investigation of the association
between ART exposure and false negative results and the
possible immunological mechanisms underpinning this
effect are outside the scope of this paper but should be a
priority.
Few studies have been conducted comparing HIV-POCT
using finger stick whole blood in field conditions with a
laboratory GS. Specificity in data from the current study
was high; we found very low levels of false positive rapid
test results, in contrast to some studies [20]. Published data
on sensitivity of HIV rapid tests in the field vary. One study
from SA nested within the Good Start Trial showed sensi-
tivity of 98% when comparing HIV-POCT tests with
laboratory-based HIV tests [10], whereas another South
African study measured accuracy of HIV-POCT testing in a
clinic setting and found high rates of false negative HIV
tests (sensitivity 69%, 95% CI: 41–89%) which was improved
by introduction of a different testing algorithm and QA
measures [13]. The authors concluded that user error was
the most significant contributor to inaccuracy.
Throughout the study period, the same HIV-POCT kits and
QA/QC procedures were used for the CHiPs intervention as in
the PC research cohort. Whilst parallel laboratory testing was
not undertaken for the community members tested by CHiPs,
we assume that similar challenges of HIV-POCT sensitivity are
likely to have occurred in that context. Thus, it was critical to
communicate the observed poor HIV-POCT performance to
the community. Throughout the conduct of the HPTN 071
(PopART) study, the study team reported the findings of HIV-
POCT performance to in-country ethics committees, study
communities and international advisory boards, the study
sponsor and Department of Health partners. In partnership
with all stakeholders, community messaging was developed
and delivered. This messaging focused on encouragement of
repeat HIV testing for all at-risk individuals to avoid missed
HIV diagnoses and consequently compromising individual
health as well as risk of onward transmission and included
reference to the fact that HIV rapid tests, like other diagnostic
tests, are not 100% accurate.
Strengths and limitations
This study was conducted in the real-world setting using HIV-
POCT as used in national algorithms and nationally approved
QA procedures. The study setting offered a unique opportu-
nity to compare HIV-POCT results to laboratory-based 4th
generation testing completed in parallel on the same indivi-
duals. The study does, however, have limitations. It is difficult
to attribute improvements in HIV-POCT sensitivity to specific
factors, as multiple components of QA intervention were
implemented concurrently with changes in test kits in SA.
However, this is exactly how these changes would be imple-
mented by national health systems. In the data shown here,
the testing was conducted by nurses and we have assumed
that similar results were seen in the HIV-POCT being done by
lay counsellors at the same time using the same test algo-
rithms and QA systems.
Conclusions
In conclusion, this is one of the first reports of wide-scale
delivery of HIV-POCT in high-burden real-world settings com-
pared to a laboratory GS. In this study, we demonstrate that
detection of HIV infection can be improved significantly with
enhanced user training, implementation of frequent and
vigilant QA and QC monitoring and consistent use of an
approved HIV-POCT algorithm. HIV RNA testing is more sen-
sitive for detecting HIV infection than 4th generation assays
but may not be feasible or affordable in some settings.
In order to reach our goals of universal knowledge of HIV
status using large-scale non-facility-based HIV testing pro-
grammes, appropriate QA procedures must be carefully
established and users must be adequately trained and
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supervised in conducting all testing procedures.
Programmes should also pay specific attention to advances
in HIV-POCT technology and new evidence evaluating HIV-
POCT in field settings, ensuring that they are using the best
option for their setting.
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